Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Poland
  4. Warsaw Stock Exchange
  5. Mabion S.A.
  6. News
  7. Summary
    MAB   PLMBION00016

MABION S.A.

(MAB)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Mabion S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021

09/16/2021 | 12:41am EST

Mabion S.A. Announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was PLN 4.432 million compared to PLN 12.351 million a year ago. Net loss was PLN 2.497 million compared to PLN 10.983 million a year ago. Basic loss per share from continuing operations was PLN 0.15 compared to PLN 0.8 a year ago. For the half year, operating loss was PLN 18.510 million compared to PLN 29.031 million a year ago. Net loss was PLN 19.572 million compared to PLN 30.829 million a year ago. Basic loss per share from continuing operations was PLN 1.21 compared to PLN 2.25 a year ago.


ę S&P Capital IQ 2021
All news about MABION S.A.
2021Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
CI
2021MABION S.A.(WSE : MAB) added to S&P Global BMI Index
CI
2021Mabion S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
2021Big pharma and private equity seek healthy returns in Europe's east
RE
2021MABION Announces Executive Changes
CI
2021Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
2021Mabion S.A. Auditor Raises 'Going Concern' Doubt
CI
2021Polish Biotech Mabion Enters Deal To Manufacture Novavax COVID-19 Jab
MT
2021Mabion Biotech Signs Deal with Novavax on Covid-19 Vaccine Technology Transfer
CI
2020Mabion S.A. Reports Earnings Results for the Third Quarter Ended September 30, 2020
CI
More news
Financials
Sales 2021 11,3 M 2,74 M 2,74 M
Net income 2021 -59,0 M -14,3 M -14,3 M
Net Debt 2021 20,8 M 5,06 M 5,06 M
P/E ratio 2021 -11,9x
Yield 2021 -
Capitalization 707 M 173 M 172 M
EV / Sales 2021 64,7x
EV / Sales 2022 2,80x
Nbr of Employees 213
Free-Float 63,7%
Chart MABION S.A.
Duration : Period :
Mabion S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MABION S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 43,75 PLN
Average target price 68,50 PLN
Spread / Average Target 56,6%
EPS Revisions
Managers and Directors
Krzysztof Kaczmarczyk President-Management Board & CEO
Grzegorz Mariusz Grabowicz Chief Financial Officer
Robert Leszek Konski Independent Member-Supervisory Board
Slawomir Jaros Chief Operating & Scientific Officer
David John James Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
MABION S.A.-28.40%173
GILEAD SCIENCES, INC.-7.35%84 382
REGENERON PHARMACEUTICALS-4.16%63 645
VERTEX PHARMACEUTICALS3.93%58 082
WUXI APPTEC CO., LTD.-12.95%47 040
BIONTECH SE-40.05%37 325